Cognition presented biomarker results from the Phase 2 SHINE (COG0201) study of zervimesine (CT1812) in mild-to-moderate Alzheimer’s disease at the AD/PD™ 2025 Alzheimer’s & Parkinson’s Diseases Conference. In an oral presentation, which is archived below, changes in key proteins, called biomarkers, in the entire study population are compared with changes observed in participants who began the study with lower levels of a protein called p-Tau217 in their blood.
Posters:
- CSF Proteomic Biomarker Analysis from Phase 2 Study SHINE Identified Effects of S2R Modulator CT1812 in Alzheimer’s Disease (view poster here)
- Identification of CSF Proteins That Correlate with Cognitive Outcomes in Participants of Phase 2 Study Shine Evaluating Effects of CT1812 in Patients with Alzheimer’s Disease (view poster here)
- Identification of Molecular Correlates with CT1812 Treatment-related Decrease in NfL CSF Levels Connected to Sigma-2 Receptor (view poster here)
Oral session:
- Positive Impact of CT1812 Treatment on Plasma Biomarkers in Lower p-tau217 Subgroup Aligns with Clinical Benefits in Mild-to-Moderate AD Patients
01 April 2025 at 2:45pm CET
Mary Hamby, Ph.D., VP of Research, Cognition Therapeutics